Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. Fundamental Analysis
Eagle Pharmaceuticals, Inc. (EGRX) shows moderate financial fundamentals with a PE ratio of 0.12, profit margin of 11.26%, and ROE of 17.39%. The company generates $0.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 68.7/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze EGRX's fundamental strength across five key dimensions:
Efficiency Score
WeakEGRX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentEGRX trades at attractive valuation levels.
Growth Score
ModerateEGRX shows steady but slowing expansion.
Financial Health Score
ExcellentEGRX maintains a strong and stable balance sheet.
Profitability Score
ModerateEGRX maintains healthy but balanced margins.
Key Financial Metrics
Is EGRX Expensive or Cheap?
P/E Ratio
EGRX trades at 0.12 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, EGRX's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Eagle Pharmaceuticals, Inc. at 0.02 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.10 times EBITDA. This is generally considered low.
How Well Does EGRX Make Money?
Net Profit Margin
For every $100 in sales, Eagle Pharmaceuticals, Inc. keeps $11.26 as profit after all expenses.
Operating Margin
Core operations generate 25.57 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $17.39 in profit for every $100 of shareholder equity.
ROA
Eagle Pharmaceuticals, Inc. generates $8.78 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Eagle Pharmaceuticals, Inc. generates limited operating cash flow of $30.92M, signaling weaker underlying cash strength.
Free Cash Flow
Eagle Pharmaceuticals, Inc. produces free cash flow of $30.92M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $2.38 in free cash annually.
FCF Yield
EGRX converts 6.95% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.12
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.001
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.02
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.01
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.29
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.70
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.17
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.27
vs 25 benchmark
How EGRX Stacks Against Its Sector Peers
| Metric | EGRX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.12 | 28.25 | Better (Cheaper) |
| ROE | 17.39% | 780.00% | Weak |
| Net Margin | 11.26% | -20122.00% (disorted) | Strong |
| Debt/Equity | 0.29 | 0.30 | Neutral |
| Current Ratio | 1.70 | 4.66 | Neutral |
| ROA | 8.78% | -14687.00% (disorted) | Weak |
EGRX outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Eagle Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation